Abstract

A REVIEW ARTICLE ON CARDIO-SELECTIVE ?- BLOCKERS IN TREATMENT OF MODERATE HYPERTENSION

Achla Sharma*, Amar Deep Ankalgi, Ankit Sharma, Priyanka Lagwal and Nikhil Kumar

ABSTRACT

This comprehensive review examines the pharmacological efficacy, safety, and clinical implications of cardioselective beta blockers in the management of moderate hypertension. Highlighting their selective antagonism of beta-1 receptors, these pharmaceutical agents play a crucial role in achieving precise regulation of blood pressure while simultaneously minimizing adverse effects on beta-2 receptors in the bronchial and peripheral vascular systems. A thorough analysis of existing empirical evidence emphasizes the consistent effectiveness of these compounds in improving cardiovascular outcomes by reducing heart rate and myocardial contractility. Beyond their primary antihypertensive effects, this review explores additional therapeutic advantages of cardioselective beta blockers, including antiarrhythmic and anti-ischemic properties, as well as a favorable impact on left ventricular function. The safety profiles of cardioselective beta blockers, including metoprolol, atenolol, bisoprolol, carvedilol, and nebivolol, support their suitability for a diverse patient population, including those with concurrent conditions such as diabetes or chronic obstructive pulmonary disease. In conclusion, this review advocates for the continued use of cardioselective beta blockers, highlighting their unique attributes and potential synergies in the nuanced management of moderate hypertension. The findings underscore the importance of tailored therapeutic approaches and provide a basis for future research efforts aimed at optimizing cardiovascular health outcomes in this specific patient population.

Keywords: Moderate Hypertension, Cardioselective ?-blocker, blood pressure, hypotension.